How effective is Mounjaro for weight loss?

In SURMOUNT-1, participants on 15mg tirzepatide lost an average of around 20–21% of their body weight over 72 weeks, with some analyses reaching ~22.5%.
Mounjaro is the only weight-loss medicine licensed in the UK that activates both the GIP and GLP-1 receptors — a dual mechanism not found in semaglutide-based treatments.
In the head-to-head SURMOUNT-5 trial (72 weeks), tirzepatide produced greater average weight loss than semaglutide 2.4mg (Wegovy).
NICE formally recommended tirzepatide for NHS use in December 2024, citing the strength of its clinical evidence across the SURMOUNT programme.

In clinical trials, Mounjaro (tirzepatide) produced average weight reductions of around 20–21% at the highest dose over 72 weeks — results that made it the most effective licensed weight-loss injection available in the UK at the time of its approval. That figure comes from SURMOUNT-1, a trial published in the New England Journal of Medicine involving 2,539 adults with obesity, none of whom had type 2 diabetes. Mounjaro is a prescription-only medicine, so a prescriber needs to assess whether it is clinically appropriate for you before treatment can begin.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the trial data actually shows, and what it means in practice

The SURMOUNT-1 results: what the numbers looked like

SURMOUNT-1 is the landmark evidence behind Mounjaro's UK licence. Over 72 weeks, adults taking 15mg tirzepatide lost an average of roughly 20–21% of their starting body weight. To put that in concrete terms: someone starting at 100kg would, on average, have lost around 20kg. At 10mg the average was approximately 19%, and at 5mg around 16%. Every arm of the trial outperformed placebo by a substantial margin.

These figures come from a setting where participants also followed a reduced-calorie diet and increased physical activity, the same conditions under which Mounjaro is licensed in the UK. The medicine works alongside lifestyle changes, not instead of them. Participants who engaged with both saw the strongest results, which is worth bearing in mind when reading the headline percentages.

For a fuller breakdown of the results data across doses, the Mounjaro effectiveness page covers each trial arm in more detail. What matters here is the overall picture: the evidence base is large, peer-reviewed, and published in one of medicine's most scrutinised journals.

How tirzepatide compares to other licensed options

Most weight-loss injections currently available in the UK target a single receptor. Mounjaro's tirzepatide is different: it activates both the GIP receptor and the GLP-1 receptor simultaneously. Both receptors are involved in appetite regulation and blood-sugar control, and the combination appears to produce effects that neither pathway achieves alone. The tirzepatide overview explains the mechanism in more detail if you want to go deeper on the science.

The head-to-head comparison with semaglutide 2.4mg (Wegovy) came in the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025. Over 72 weeks, tirzepatide produced greater average weight reduction, a finding NICE noted when it appraised both medicines. NICE's appraisal of tirzepatide (TA1026), published in December 2024, formally recommended it for NHS use, citing the strength of the SURMOUNT programme evidence. That recommendation itself is a signal of how seriously the clinical community takes these results.

There is evidence that timing and dose level both matter. When Mounjaro tends to work best is covered separately, but the short version is that most people see the clearest changes after reaching their maintenance dose and after a period of consistent use.

What affects how effective Mounjaro is for any individual

Trial averages tell you what happened across thousands of people; they do not predict what will happen for you specifically. A few things are known to influence individual response. Adherence to the dosing schedule matters, skipping injections or not titrating to the recommended dose reduces exposure to the medicine. Appetite suppression works best when paired with protein-adequate meals and staying well hydrated, since much of Mounjaro's mechanism involves slowing gastric emptying and signalling fullness to the brain.

Physical activity also plays a genuine role. Resistance training in particular helps preserve lean muscle during significant weight loss, which matters for long-term metabolic health. The guide to exercising on Mounjaro covers what the evidence says about combining the two. Separately, practical strategies for getting the most from treatment are worth reading before you start, not just if progress stalls.

On a practical note: Mounjaro pens need to be kept in the fridge between uses, ideally somewhere consistent, many people keep theirs on the same shelf next to other regular items so the weekly dose becomes part of a routine rather than an afterthought. Routine matters more than people expect.

If you are thinking about cost alongside effectiveness, the Mounjaro prices page sets out what private treatment typically involves and what a single transparent price should include. A prescription medicine's value is measured differently from a consumer product, the clinical oversight around it is part of what makes it safe to use. If you would like a prescriber to assess whether Mounjaro is right for you, you can start a free consultation with our clinical team today.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions